Efficacy, Safety, and Pharmacokinetics Study of CJM112 in Hidradenitis Suppurativa Patients
Status:
Completed
Trial end date:
2016-11-23
Target enrollment:
Participant gender:
Summary
This is a randomized, double blind, multicenter study in patients with moderate to severe
chronic hidradenitis suppurativa in parallel groups, to determine the efficacy and safety of
multiple doses of CJM112 in comparison to placebo. The study has two periods to explore
preliminary dose effects.